5
Centuple Global
RUBRAMEDICAMENTSLTD NSE
Centuple Global
HealthcareNSE: RUBRAMEDICAMENTSLTD BSE: 531099 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹18.72 Cr
Volatility
Moderate
P/E Ratio
15.9
EBITDA
₹2.28 Cr
Return on Equity
4.55%
Debt to Equity
0.3
Book Value
₹42.47
EPS
₹0.06
52W High
₹144.4
52W Low
₹31.62
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Stock is trading at 0.82 times its book value
- Company's median sales growth is 26.2% of last 10 years
- Company's working capital requirements have reduced from 182 days to 14.7 days
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.3% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 215 days.
Growth Rate
Revenue Growth
—
Net Income Growth
—
Cash Flow Change
0.19%
ROE
-19.75% lower than
3Y
ROCE
102% higher than
3Y
EBITDA Margin (Avg.)
-96.4% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.2 | 0.29 | 0.17 | 0.47 | 0.1 | 0.05 | 0.1 | 0.25 | 11.71 | 109 | 174 | 279 | 0 |
| Expenses | 0.25 | 0.03 | 0.11 | 0.71 | 0.07 | 0.08 | 0.14 | 0.16 | 11.62 | 107 | 173 | 280 | 0.18 |
| Operating Profit | -0.05 | 0.26 | 0.06 | -0.24 | 0.03 | -0.03 | -0.04 | 0.09 | 0.09 | 1.8 | 0.77 | -0.37 | -0.18 |
| OPM % | -25% | 89.66% | 35.29% | -51.06% | 30% | -60% | -40% | 36% | 0.77% | 1.66% | 0.44% | -0.13% | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | -0.02 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.05 | 0.26 | 0.06 | -0.24 | 0.03 | -0.03 | -0.02 | 0.07 | 0.09 | 1.8 | 0.77 | -0.37 | -0.18 |
| Tax % | 0% | 0% | 0% | -4.17% | 0% | 33.33% | 0% | 0% | 0% | 26.11% | 25.97% | 27.03% | 0% |
| Net Profit | -0.05 | 0.26 | 0.06 | -0.23 | 0.02 | -0.04 | -0.02 | 0.06 | 0.09 | 1.32 | 0.57 | -0.48 | -0.18 |
| EPS in Rs | -0.09 | 0.48 | 0.11 | -0.42 | 0.04 | -0.07 | -0.04 | 0.11 | 0.16 | 2.41 | 1.04 | -0.88 | -0.33 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 574 | 562 |
| Expenses | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 572 | 560 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| OPM % | — | -5% | 10% | -1.3% | -31% | 2% | 2% | -1% | -7% | 2.6% | 20% | 0.4% | 0.4% |
| Other Income | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 20% | 0% | 50% | 0% | -50% | 40% | 34% | — |
| Net Profit | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| EPS in Rs | -5.61 | -0.02 | 0.05 | -0.29 | -0.02 | 0.05 | 0.02 | -0.07 | -0.15 | 0.05 | 0.05 | 2.76 | 2.24 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | 18 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 |
| Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 313 |
| Total Liabilities | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 343 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 343 |
| Total Assets | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 343 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | -28 |
| Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 28 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | -28 |
| CFO/OP | 114 | 100 | 133 | -600 | 17 | 650 | 5,200 | 2,450 | -12 | 0 | 190 | -1,223 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | 36 | 24 | 54 | 179 | 107 | 164 | 122 | 135 | 229 | 212 | 215 |
| Inventory Days | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | 1 |
| Days Payable | — | — | — | — | — | — | — | — | — | — | — | 197 |
| Cash Conversion Cycle | — | 36 | 24 | 54 | 179 | 107 | 164 | 122 | 135 | 229 | 212 | 19 |
| Working Capital Days | — | 18 | -35 | 36 | 260 | 221 | 60 | 98 | 129 | 145 | 387 | 15 |
| ROCE % | -3% | -3% | 7% | 25% | -31% | 3% | 2% | -3% | -13% | 3% | 17% | 15% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Centuple Global insights
57 extracted metrics + investor summaries across FY09–FY26.
Documents
2
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
29 Apr - Company confirms it is not a Large Corporate Entity; FY2025-26 debt borrowing was 6.73 crore. 29 Apr - Company confirms it is not a Large Corporate Entity; FY2025-26 debt borrowing was 6.73 crore.
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
29 Apr - Centuple Global confirms it is not a large corporate; borrowings stood at ₹6.73 crore on March 31, 2026. 29 Apr - Centuple Global confirms it is not a large corporate; borrowings stood at ₹6.73 crore on March 31, 2026.
4
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
29 Apr - Company confirms it is not a Large Corporate Entity; FY2025-26 debt borrowing was 6.73 crore. 29 Apr - Company confirms it is not a Large Corporate Entity; FY2025-26 debt borrowing was 6.73 crore.
5
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
29 Apr - Centuple Global confirms it is not a large corporate; borrowings stood at ₹6.73 crore on March 31, 2026. 29 Apr - Centuple Global confirms it is not a large corporate; borrowings stood at ₹6.73 crore on March 31, 2026.
Frequently Asked Questions about Centuple Global
What does Centuple Global Ltd do?
Incorporated in 1991, Checkpoint Trends Ltd is in the business of trading and consultancy[1]
Where is Centuple Global Ltd (531099) listed?
Centuple Global Ltd trades as RUBRAMEDICAMENTSLTD on the NSE and under code 531099 on the BSE.
Which sector does Centuple Global Ltd belong to?
Centuple Global Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Centuple Global Ltd?
Centuple Global Ltd has a market capitalisation of ₹18.72 Cr, which places it in the Small Cap band.
What is the PE ratio of Centuple Global Ltd?
Centuple Global Ltd trades at a PE ratio of 15.90, on earnings per share of ₹0.06, against a book value of ₹42.47 per share.
What is the 52-week high and low of Centuple Global Ltd?
Over the last 52 weeks Centuple Global Ltd has traded between ₹31.62 and ₹144.4.
What is the Return on Equity (ROE) of Centuple Global Ltd?
Centuple Global Ltd reported a return on equity of 4.55%. Its debt-to-equity ratio is 0.30.
Company Information
Incorporated in 1991, Checkpoint Trends Ltd is in the business of trading and consultancy[1]
Website rubramed.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531099.md for Centuple Global Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.